Dear Colleagues,
We are pleased to announce the “Cancers 2023 Best Paper Award” for research and review articles published in Cancers from 1 January 2023 to 31 December 2023. Two reviews and two research articles will receive an award each. The papers will be selected after a thorough evaluation by the journal Award Committee led by the Editor-in-Chief, Prof. Dr. Samuel C. Mok.
Eligibility for the Award:
– Papers published in Cancers from 1 January 2023 to 31 December 2023;
– Open to all career levels;
– Both regular and Special Issue submissions will be considered.
Selection Criteria:
The papers will be selected by the journal Award Committee according to the following criteria:
– Scientific merit and broad impact;
– Originality of the research objectives and/or the ideas presented;
– Creativity of the study design or uniqueness of the approaches and concepts;
– Clarity of presentation;
– Citations and downloads.
The Prize:
Two review awards and two research article awards will each receive CHF 500, an electronic certificate and a chance to publish a paper free of charge in Cancers before the end of June 2026 after peer review.
The winners will be announced on the journal website in June 2025.
Kind regards,
Cancers Editorial Office
Cancers 2023 Best Paper Award
Winner announcement: 30 June 2025
Eligibility and Requirements
– All papers published in Cancers will be eligible (Both regular and Special Issue submissions).
Winner
Open AccessArticle
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
by
Matteo Bauckneht, Carlo Genova, Giovanni Rossi, Erika Rijavec, Maria Giovanna Dal Bello, Giulia Ferrarazzo, Marco Tagliamento, Maria Isabella Donegani, Federica Biello, Silvia Chiola, Lodovica Zullo, Stefano Raffa, Francesco Lanfranchi, Giuseppe Cittadini, Cecilia Marini, Egesta Lopci, Gianmario Sambuceti, Francesco Grossi and Silvia Morbelli
Winner
Open AccessEditor’s ChoiceArticle
Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells
by
Timothy Crook, Robert Leonard, Kefah Mokbel, Alastair Thompson, Michael Michell, Raymond Page, Ashok Vaid, Ravi Mehrotra, Anantbhushan Ranade, Sewanti Limaye, Darshana Patil, Dadasaheb Akolkar, Vineet Datta, Pradip Fulmali, Sachin Apurwa, Stefan Schuster, Ajay Srinivasan and Rajan Datar
Open AccessEditor’s ChoiceArticle
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
by
Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Monika Braun, Doris Brechtefeld, Christian Krendl, Christiane Geiger, Kathrin Mutze, Elfriede Noessner, Dolores J. Schendel, Maja Bürdek, Susanne Wilde and Daniel Sommermeyer
Award Committee
Dr. Samuel Mok
Chairman
UT MD Anderson Cancer Center
Prof. Donat Kögel
Klinikum der Goethe-Universität Frankfurt
Dr. Nicola Amodio
Università Magna Graecia di Catanzaro
Winner
John Maher
King’s College London, School of Cancer and Pharmaceutical Studies, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK
https://www.mdpi.com/2072-6694/11/5/674
Barbara Wegiel
Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
https://www.mdpi.com/2072-6694/11/4/450
Massimo Libra
Department of Biomedical and Biotechnological Sciences, Oncologic, Clinic and General Pathology Section, University of Catania, 95123 Catania, Italy
https://www.mdpi.com/2072-6694/11/1/38
Anthony Gonçalves
Department of Medical Oncology, Aix-Marseille University, Inserm U1068, CNRS UMR7258, Institute Paoli-Calmettes, 13009 Marseille, France
https://www.mdpi.com/2072-6694/11/7/1033
Award Committee
Dr. Samuel Mok
Chairman
UT MD Anderson Cancer Center